Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 7/2015

01-07-2015 | Adis Diagnostic Evaluation

[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment

Authors: Yahiya Y. Syed, Emma Deeks

Published in: CNS Drugs | Issue 7/2015

Login to get access

Abstract

Intravenous 18F-labelled florbetaben ([18F]florbetaben) [Neuraceq™] is a polyethylene glycol stilbene derivative that is approved in the USA, EU and South Korea for positron emission tomography (PET) imaging of the brain. It is used to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive impairment. In vitro, [18F]florbetaben has high affinity and selectivity for β-amyloid. It has a short PET scan time (15–20 min). Visual assessment of regional and whole brain [18F]florbetaben PET images detected brain β-amyloid with high sensitivity and specificity, with good inter-reader agreement, in a phase III study in patients with various levels of cognitive function when compared with postmortem histopathological assessment. The whole brain visual assessment displayed high positive and negative predictive values, enabling amyloid pathology to be reliably detected or excluded. Quantitative PET analyses were generally consistent with the visual assessments. [18F]florbetaben was generally well tolerated in clinical trials. All adverse reactions in [18F]florbetaben recipients were mild to moderate in severity and the most common were injection-site-related (erythema, irritation and pain). There were no serious adverse reactions related to [18F]florbetaben. In summary, [18F]florbetaben is a highly accurate β-amyloid PET tracer that has the potential to support the clinical diagnosis of Alzheimer’s disease and other causes of cognitive decline.
Literature
1.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.CrossRefPubMed
2.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.CrossRefPubMed
3.
Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):257–62.PubMedCentralCrossRefPubMed
4.
5.
Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52(11):1733–40.PubMed
6.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.CrossRefPubMed
7.
Mathis CA, Mason NS, Lopresti BJ, et al. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med. 2012;42(6):423–32.PubMedCentralCrossRefPubMed
8.
Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129–35.CrossRefPubMed
9.
Zhang W, Oya S, Kung MP, et al. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol. 2005;32(8):799–809.CrossRefPubMed
10.
11.
12.
Ni R, Gillberg PG, Bergfors A, et al. Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain. 2013;136(7):2217–27.CrossRefPubMed
13.
Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, et al. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Nucl Med Biol. 2012;39(7):1042–8.CrossRefPubMed
14.
15.
Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54(7):1127–34.CrossRefPubMed
16.
Brendel M, Jaworska A, Herms J, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry. 2015;. doi:10.​1038/​mp.​2015.​74.PubMed
17.
18.
Senda M, Sasaki M, Yamane T, et al. Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging. 2015;42(1):89–96.PubMedCentralCrossRefPubMed
19.
Patt M, Schildan A, Barthel H, et al. Metabolite analysis of [18F]florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanal Nucl Chem. 2010;284(3):557–62.CrossRef
20.
Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.CrossRefPubMed
21.
Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702–14.CrossRefPubMed
22.
Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.CrossRefPubMed
23.
Sabri O, Seibyl J, Ishihara K, et al. Close to clinical routine phase 2 trial on florbetaben PET imaging of β-amyloid (Aβ) in Alzheimer’s disease (AD) [abstract no. 299]. J Nucl Med. 2013;54(Suppl 2).
24.
Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9.CrossRefPubMed
25.
26.
Jennings D, Seibyl J, Sabbagh M, et al. Age dependence of brain β-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology. 2015;84(5):500–7.CrossRefPubMed
27.
Ong KT, Villemagne VL, Bahar-Fuchs A, et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86(4):431–6.CrossRefPubMed
28.
US Food and Drug Administration. Neuraceq (florbetaben F 18 injection): clinical pharmacology and biopharmaceutics review(s). 2014. http://​www.​fda.​gov/​. Accessed 13 Mar 2015.
29.
Sattler B, Barthel H, Patt M, et al. Radiation exposure by [F18]florbetaben, a new PET tracer for detection of cerebral β-amyloid in Caucasian and Asian healthy volunteers [abstract no. OP432]. Eur J Nucl Med Mol Imaging. 2010;37(Suppl 2):S274.
30.
O’Keefe GJ, Saunder TH, Ng S, et al. Radiation dosimetry of β-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009;50(2):309–15.CrossRefPubMed
31.
32.
Seibyl J, Barthel H, Stephens A, et al. Reliability, reproducibility and efficacy of the 18F florbetaben β-amyloid PET scan visual assessment method as trained via a computer-based instructional tool [abstract no. 300]. J Nucl Med. 2013;54(Suppl 2).
33.
34.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.PubMedCentralCrossRefPubMed
35.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.PubMedCentralCrossRefPubMed
36.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedCentralCrossRefPubMed
37.
American Psychiatric Association. Neurocognitive disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
38.
Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):e-1–16.
39.
Schipke CG, Peters O, Heuser I, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(6):416–22.CrossRefPubMed
40.
Saidlitz P, Voisin T, Vellas B, et al. Amyloid imaging in Alzheimer’s disease: a literature review. J Nutr Health Aging. 2014;18(7):723–40.CrossRefPubMed
41.
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1–15 e1–4.
42.
Metadata
Title
[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment
Authors
Yahiya Y. Syed
Emma Deeks
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 7/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-015-0258-7

Other articles of this Issue 7/2015

CNS Drugs 7/2015 Go to the issue

Review Article

The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

Review Article

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

Original Research Article

Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case–Control Analysis

Current Opinion

Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics

Review Article

Propofol: A Review of its Role in Pediatric Anesthesia and Sedation

Leading Article

The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia